TY - JOUR
T1 - Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer
AU - Tanderup, Kari
AU - Nesvacil, Nicole
AU - Kirchheiner, Kathrin
AU - Serban, Monica
AU - Spampinato, Sofia
AU - Jensen, Nina Boje Kibsgaard
AU - Schmid, Maximilian
AU - Smet, Stephanie
AU - Westerveld, Henrike
AU - Ecker, Stefan
AU - Mahantshetty, Umesh
AU - Swamidas, Jamema
AU - Chopra, Supriya
AU - Nout, Remi
AU - Tan, Li Tee
AU - Fokdal, Lars
AU - Sturdza, Alina
AU - Jürgenliemk-Schulz, Ina
AU - de Leeuw, Astrid
AU - Lindegaard, Jacob Christian
AU - Kirisits, Christian
AU - Pötter, Richard
PY - 2020/10
Y1 - 2020/10
N2 - The last 2 decades have witnessed the development and broad adoption of image-guided adaptive brachytherapy (IGABT) combined with radiochemotherapy in patients with locally advanced cervical cancer. A variety of brachytherapy techniques and dose/fractionation schedules have been applied, and until recently, there was no strong evidence available for preferring one approach to another. However, large volumes of data have now provided high level clinical evidence for dose-effect relations for both disease and morbidity endpoints. It is therefore now possible to apply evidence based dose planning aims and dose prescription protocols in IGABT for locally advanced cervical cancer. This review gives an overview of targets/organs-at-risk and disease/morbidity endpoints which are relevant in the context of treatment planning and dose prescription in IGABT. The dosimetric and clinical evidence is summarized to support the implementation of dose prescription protocols which include hard and soft constraints for targets and organs at risk.
AB - The last 2 decades have witnessed the development and broad adoption of image-guided adaptive brachytherapy (IGABT) combined with radiochemotherapy in patients with locally advanced cervical cancer. A variety of brachytherapy techniques and dose/fractionation schedules have been applied, and until recently, there was no strong evidence available for preferring one approach to another. However, large volumes of data have now provided high level clinical evidence for dose-effect relations for both disease and morbidity endpoints. It is therefore now possible to apply evidence based dose planning aims and dose prescription protocols in IGABT for locally advanced cervical cancer. This review gives an overview of targets/organs-at-risk and disease/morbidity endpoints which are relevant in the context of treatment planning and dose prescription in IGABT. The dosimetric and clinical evidence is summarized to support the implementation of dose prescription protocols which include hard and soft constraints for targets and organs at risk.
UR - http://www.scopus.com/inward/record.url?scp=85087790876&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.semradonc.2020.05.008
DO - https://doi.org/10.1016/j.semradonc.2020.05.008
M3 - Review article
C2 - 32828387
SN - 1053-4296
VL - 30
SP - 311
EP - 327
JO - Seminars in radiation oncology
JF - Seminars in radiation oncology
IS - 4
ER -